Pocket Guide

www.cardiometabolichealth.org

POCKET GUIDE

October 2 − 5, 2013 · Sheraton Hotel · Boston, MA

Cardiometabolic Health Congress

2013

Pocket Guide Sponsor

Pocket Guide

Visit www.Qsymia.com to learn more

about this FDA-approved therapy.

For any questions, please call VIVUS Medical Information at 1-888-998-4887.© 2013 VIVUS, Inc. All rights reserved. 100425.01-USP

SIGN-OFF Date Time OK Correx QueryStudio ManagerTraffi cVisual QCEditorCopywriterCopy SupervisorArt DirectorArt SupervisorAcct. ExecutiveAcct. ExecutiveProduction

COMMENTSDRAFTFCB HealthCare CAD Router

2VVS_QNXA_I0866 CMHC Pocket Guide

Job #: 2VVS_QNXA_I0866File Name: I0866_CMHC_PktGuide_FR.inddLocation: PrePress ServerClient: VivusProduct: QsymiaLive Area: 4.75" x 6.75"Trim: 5" x 7"Bleed: 5.25" x 7.25"Colors: 4C

Art Director: Dave R. (x 3671)Production: Joe B (x2895)Traffi c Person: Tatiana A (x 3174)Mac Operator: tpDate: August 19, 2013 4:21 PMRound: FR

S:4.75”S:6.75”

T:5”T:7”

B:5.25”B:7.25”

I0866_CMHC_PktGuide_FR.indd 2 8/19/13 4:26 PM

Table of Contents

Welcome Message . . . . . . . . . . . . . . . . . . . . . . 4

Hours of Operation . . . . . . . . . . . . . . . . . . . . . 5

Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5

Schedule-at-a-Glance . . . . . . . . . . . . . . . . . . . 6

Program Overview . . . . . . . . . . . . . . . . . . . . . . 8

Accreditation . . . . . . . . . . . . . . . . . . . . . . . . . . 10

Chairpersons . . . . . . . . . . . . . . . . . . . . . . . . . . 12

Distinguished Faculty . . . . . . . . . . . . . . . . . . 12

Agenda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16

Industry Supporters & Sponsors . . . . . . . 25

Association Supporters . . . . . . . . . . . . . . . . 26

Exhibitors Guide . . . . . . . . . . . . . . . . . . . . . . . 30

Publication Supporters . . . . . . . . . . . . . . . . 41

2013

3

Table of Contents

Visit www.Qsymia.com to learn more

about this FDA-approved therapy.

For any questions, please call VIVUS Medical Information at 1-888-998-4887.© 2013 VIVUS, Inc. All rights reserved. 100425.01-USP

SIGN-OFF Date Time OK Correx QueryStudio ManagerTraffi cVisual QCEditorCopywriterCopy SupervisorArt DirectorArt SupervisorAcct. ExecutiveAcct. ExecutiveProduction

COMMENTSDRAFTFCB HealthCare CAD Router

2VVS_QNXA_I0866 CMHC Pocket Guide

Job #: 2VVS_QNXA_I0866File Name: I0866_CMHC_PktGuide_FR.inddLocation: PrePress ServerClient: VivusProduct: QsymiaLive Area: 4.75" x 6.75"Trim: 5" x 7"Bleed: 5.25" x 7.25"Colors: 4C

Art Director: Dave R. (x 3671)Production: Joe B (x2895)Traffi c Person: Tatiana A (x 3174)Mac Operator: tpDate: August 19, 2013 4:21 PMRound: FR

S:4.75”

S:6.75”

T:5”

T:7”

B:5.25”

B:7.25”

I0866_CMHC_PktGuide_FR.indd 2 8/19/13 4:26 PM

4

2013

WELCOME!

Welcome to the 8th Annual Cardiometabolic Health Congress (CMHC).

We are pleased you have joined us, our world-renowned expert

faculty, 42 prestigious medical associations, and your peers to combat

the global health crisis emanating from cardiovascular and metabolic

disease.

It is impossible to separate cardiovascular from metabolic disease

when it comes to risk assessment, prevention, and clinical

intervention. No other conference addresses the breadth and depth

of this new paradigm like the CMHC – translating the most current

clinical information into real-world solutions that will undoubtedly

make a significant impact on your daily practice.

Enclosed you will find the CMHC schedule-at-a-glance and detailed

agenda, as well as information on our distinguished faculty and

corporate-supported and sponsored symposia. Should you require

assistance during your stay, please do not hesitate to visit the

CMHC Registration Desk located on the Second Floor of the

Sheraton Boston Hotel.

Enjoy your stay in Boston!

Warm regards,

George L. Bakris, MD

University of Chicago

Pritzker School of Medicine

Christie M. Ballantyne, MD

Methodist DeBakey Heart Center

Baylor College of Medicine

Robert H. Eckel, MD

University of Colorado

Anschutz Medical Campus

Jay S. Skyler, MD, MACP

University of Miami

Miller School of Medicine

Hours of O

peration2013 Cardiometabolic Health CongressHours of Operation Registration Desk - Second Floor - Sheraton Hotel Wednesday, October 2 10:00am – 8:00pmThursday, October 3 6:00am – 6:00pm Friday, October 4 6:00am – 6:00pmSaturday, October 5 6:00am – 12:30pm

Exhibit Hall - Hynes Convention CenterThursday, October 3 9:30am – 12:00pm 2:30pm – 6:45pmFriday, October 4 9:00am – 12:00pm 2:00pm – 5:00pm

Welcome Reception - Exhibit Hall (Hynes Convention Center)Thursday, October 3 5:30pm – 6:30pm

Sheraton Hotel Second Floor

CMHCRegistration

To Hynes Convention

Center

5

6

Sche

dule

-at-

a-G

lanc

eSchedule-at-a-Glance

Wednesday, October 2, 201312:00pm - 1:30pm Lunch Symposium (non-CME)* Republic Ballroom

1:30pm - 2:45pm Afternoon Symposium (non-CME)* Constitution Ballroom

2:45pm - 4:00pm Afternoon Symposium (non-CME)* Back Bay Ballroom

2:45pm - 4:00pm Afternoon Symposium (non-CME)* Grand Ballroom

4:00pm - 5:15pm Afternoon Symposium* Republic Ballroom

5:15pm - 6:45pm Early Evening Symposium (non-CME)* Constitution Ballroom

7:00pm - 8:30pm Dinner Symposium (non-CME)* Back Bay Ballroom 7:00pm - 8:30pm Dinner Symposium (non-CME)* Grand Ballroom

Thursday, October 3, 20136:15am - 7:45am Breakfast Symposium* Back Bay Ballroom

6:15am - 7:45am Breakfast Symposium* Constitution Ballroom

8:00am - 10:00am General Session Grand Ballroom

10:00am - 11:00am Exhibit Hall Break Hynes Convention Center

11:00am - 12:00pm General Session Grand Ballroom

12:15pm - 1:45pm Lunch Symposium* Republic Ballroom

12:15pm - 1:45pm Lunch Symposium* Back Bay Ballroom

12:15pm - 1:45pm Lunch Symposium* Constitution Ballroom

2:00pm - 3:30pm General Session Grand Ballroom

3:30pm - 4:15pm Exhibit Hall Break Hynes Convention Center

4:15pm - 5:15pm General Session Grand Ballroom

5:30pm - 6:30pm Welcome Reception Hynes Convention Center

7:00pm - 9:00pm Dinner Symposium* Back Bay Ballroom

7:00pm - 9:00pm Dinner Symposium* Constitution Ballroom

* Pre-registration is required to attend these sessions.

Stay Connected with the CMHC

7

Schedule-at-a-Glance

* Pre-registration is required to attend these sessions.

Friday, October 4, 20136:15am - 7:45am Breakfast Symposium* Back Bay Ballroom

6:15am - 7:45am Breakfast Symposium* Constitution Ballroom

8:00am - 9:50am General Session Grand Ballroom

9:50am - 10:50am Exhibit Hall Break Hynes Convention Center

10:50am - 12:15pm General Session Grand Ballroom

12:30pm - 2:00pm Lunch Symposium* Constitution Ballroom

12:30pm - 2:00pm Lunch Symposium* Back Bay Ballroom

2:15pm - 3:15pm General Session Grand Ballroom

3:15pm - 4:00pm Exhibit Hall Break Hynes Convention Center

4:00pm - 5:30pm General Session Grand Ballroom

6:30pm - 8:30pm Dinner Symposium* Constitution Ballroom

6:30pm - 8:30pm Dinner Symposium* Back Bay Ballroom

Saturday, October 5, 20136:15am - 7:45am Breakfast Symposium* Constitution Ballroom

8:00am - 12:30pm General Session Grand Ballroom

www.CardiometabolicHealth.org

Facebook.com/CardiometabolicHealth

Cardiometabolic Health Congress

Twitter.com/CMHC_CME

Blog.cardiometabolichealth.org

Stay Connected with the CMHC

Program Overview

Statement of Need*The ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care professionals in the United States. The prevalence of most cardiometabolic risk factors—especially hypertension, diabetes, and obesity—continues to rise. In the years ahead, American physicians should expect to treat unprecedented numbers of patients at high risk for morbidity and mortality from cardiovascular disease. In 2000, approximately 32% of U.S. adults had the metabolic syndrome, a constellation of cardiometabolic risk factors including excessive abdominal fat, insulin resistance, dyslipidemia, and hypertension. Today, that figure has climbed to 34% and may even be as high as 38%, depending on the criteria used to define the syndrome.

Cardiometabolic Risk Factors Are Undertreated and Difficult to ManageDespite the well-documented risks of unchecked diabetes, obesity, hypertension, and dyslipidemia, these conditions are commonly undertreated. Even when treated, they remain stubbornly difficult to manage.

• Half or more of treated patients with diabetes fail to meet recommended target HbA1c goals. Analyses of data from National Health and Nutrition Examination surveys found that only one-half to one-third of treated patients achieve the American Diabetes Association’s recommended HbA1c target of 7% or less. In addition, a report released by the American Association of Clinical Endocrinologists stated that two out of three patients with type 2 diabetes were not achieving the Association’s recommended HbA1c goal of 6.5% or less.

• When it comes to first-line therapy for obesity—diet and exercise—few patients succeed, and any improvements are usually modest. Current pharmacotherapy options are limited. Available obesity drugs have, to date, produced only modest weight loss in most patients and have been linked to adverse gastrointestinal effects and mood disorders. Furthermore, many clinicians do not address diet and exercise for weight loss with their patients, citing a lack of belief that lifestyle changes can work, lack of understanding of how to counsel patients about lifestyle change, and inadequate amounts of time and personnel.

• Only 71% of patients with hypertension are receiving any form of treatment. Of these, less than half (48%) have their blood pressure under control; hypertension remains uncontrolled in 52% of treated patients.

• Less than half of those who qualify for any kind of lipid-modifying treatment to reduce their risk of coronary heart disease are receiving it. In fact, less than half of even the highest-risk individuals—those with symptomatic coronary heart disease—are receiving lipid-lowering treatment. Of those being treated, only about one-third are achieving target goals.8

Prog

ram

Ove

rvie

w

Program Overview

Conclusion

Healthcare professionals play a major role in stemming the future burden of cardiovascular disease, diabetes, and associated comorbidities by employing aggressive strategies for the early identification and comprehensive management of patients presenting with multiple cardiometabolic risk factors. The 2013 Cardiometabolic Health Congress will translate the latest cutting-edge medical research into practical, clinical approaches for preventing, delaying, and managing cardiovascular and metabolic risk. The goal is to provide the medical community with evidence-based interventions to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.

Purpose Statement

The goal of the Congress is to improve patient outcomes through early identification and intervention strategies for patients with, or at risk of developing, diabetes and vascular disease.

Target Audience & Learning ObjectivesThe CMHC is designed for advanced-level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk. At the end of the Congress, participants will be able to:

• Explain the interrelationships among the various cardiometabolic risk factors, their impact on cardiovascular health, and their common comorbidities.

• Translate evidence-based strategies for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice.

• Identify which interventions, including lifestyle changes and various drugs in combination, are most appropriate for particular patients based on their risk profiles.

• Identify how novel and emerging therapies can be integrated into clinical practice to reduce morbidity and mortality from cardiovascular and metabolic disease.

* To access the 2013 CMHC full statement of need and reference list, please visit www.cardiometabolichealth.org/accreditation.asp.

9

Program O

verview

10

Accr

edita

tion

Physician AccreditationThis activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical Education Resources and HealthScience Media, Inc. Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.

Credit DesignationMedical Education Resources designates this live activity for a maximum of 27.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP – American Academy of Family PhysiciansThis live activity, 2013 Cardiometabolic Health Congress, with a beginning date of October 2, 2013, has been reviewed and is acceptable for up to 27.75 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP – American Academy of Nurse PractitionersThis program is approved for 27.75 contact hours of continuing education (which includes 23.75 hours of pharmacology) by the American Association of Nurse Practitioners. Program ID 1307294.

ANCC – Nursing AccreditationMedical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.This CE activity provides 27.75 contact hours of continuing nursing education.Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 27.75 contact hours.

Registered Dietitian AccreditationMedical Education Resources (Provider Number ME110) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 27.75 continuing professional education units (CPEUs) for completion of this program/material.

Earn 27 .75 CME Credits

Accreditation

Pharmacy Accreditation Medical Education Resources (MER) is accredited by the Accreditation

Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 27.75

contact hours (2.775 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Program Number – 0816-0000-13-036-L01-P) There is a registration fee for this educational activity. This activity is certified as Knowledge based CPE.

Attention Certified Diabetes Educators: The 2013 Cardiometabolic Health Congress (CMHC) is accredited by Medical Education Resources (MER). MER is accredited by the ACCME, ANCC, ACPE, and the CDR to provide continuing medical education. All of these accredited organizations are recognized by the AADE when applying for CDE renewal of certification or for initial certification

Disclosure of Conflicts of InterestIt is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

How to Obtain Your CE CreditTo obtain CE credit, please return your completed 2013 Cardiometabolic Health Congress evaluation form to HealthScience Media, Inc.

• On-site: Please return your completed evaluation form in the evaluation drop box outside the general session room.

• Post-conference: Please fax your completed evaluation form to 866.218.9168. Evaluation forms must be received by November 8, 2013. Forms received after this date will not be accepted. No exceptions.

Certificates will be mailed directly to the address indicated on your evaluation form within ten (10) weeks of the date of submission.

11

Accreditation Accreditation

George L. Bakris, MDProfessor of MedicineDirector, ASH Comprehensive Hypertension CenterUniversity of Chicago MedicinePritzker School of Medicine

Christie M. Ballantyne, MDProfessor of MedicineChief, Section of Cardiovascular ResearchChief, Section of CardiologyDepartment of Medicine, Baylor College of MedicineDirector, Center for Cardiovascular Disease PreventionBaylor College of Medicine Methodist DeBakey Heart Center

Robert H. Eckel, MD Professor of MedicineDivision of Endocrinology, Metabolism and DiabetesProfessor of Physiology and BiophysicsCharles A. Boettcher II Chair in AtherosclerosisDirector, Discovery TranslationColorado Clinical & Translational Science InstituteUniversity of Colorado Anschutz Medical CampusDirector, Lipid Clinic, University Hospital

Jay S. Skyler, MD, MACPProfessor of Medicine, Pediatrics, and PsychologyDivision of Endocrinology, Diabetes and MetabolismUniversity of Miami Miller School of MedicineDeputy Director for Clinical and Academic ProgramsDiabetes Research Institute

12

Dis

tingu

ishe

d Fa

culty

Chairpersons

Distinguished FacultyRajiv Agarwal, MDProfessor of MedicineIndiana University School of Medicine

Caroline Apovian, MDProfessor of MedicineBoston University School of MedicineDirectorCenter for Nutrition and Weight ManagementBoston Medical Center

Louis Aronne, MDDir., Comprehensive Weight Control ProgramNew York-Presbyterian HospitalClinical Professor of MedicineWeill-Cornell Medical College

Harold Bays, MDMedical Director/PresidentLouisville Metabolic and Atherosclerosis Research Center, Inc.

David S. H. Bell, MBClinical Professor of MedicineUniversity of Alabama Medical School DirectorSouthside Endocrinology

Deepak L. Bhatt, MD, MPHChief of CardiologyVA Boston Healthcare System Dir., Integrated Interventional CV ProgramBrigham and Women’s Hospital Senior Investigator, TIMI Study GroupProfessor, Harvard Medical School

Thomas Blevins, MDChief of EndocrinologySeton Hospital & St. David’s Medical CenterDirectorTexas Diabetes & Endocrinology

Robert Brook, MDAssociate Professor of MedicineDivision of Cardiovascular MedicineUniversity of Michigan

Eliot Brinton, MDDirector of the Metabolism Section ofCardiovascular GeneticsAssociate ProfessorUniversity of Utah School of Medicine

Matthew Budoff, MDProfessor of MedicineDavid Geffen School of MedicineProgram Director, CardiologyHarbor-UCLA Medical Center

Robert Busch, MDEndocrinologistThe Endocrine Group

John Buse, MDVerne S. Caviness Distinguished ProfessorChief, Division of EndocrinologyDirector, Diabetes Care CenterExecutive Associate Dean, Clinical ResearchUniv. of North Carolina School of Medicine

Sonia Caprio, MDProfessorYale School of MedicinePediatric EndocrinologistYale Medical Group

Glenn Chertow, MDNorman S. Coplon/Satellite Healthcare Professor of MedicineChief, Division of NephrologyStanford University School of Medicine

Distinguished Faculty

13

Distinguished FacultyRobert Chilton, DOProfessor of MedicineDirector, Cardiac Catheterization LabUniversity of Texas Health Science Center

William Cushman, MDProf. of Preventive Medicine and MedicineUniversity of Tennessee Health Science Ctr. in MemphisChief, Preventive MedicineVeterans Affairs Medical Center in Memphis

Samuel Dagogo-Jack, MDProfessor of MedicineDirector, Division of Endocrinology,Diabetes & MetabolismA. C. Mullins Chair in Translational ResearchUniversity of Tennessee Health Science Center

Paresh Dandona, MDFounder, Diabetes-Endocrinology Center of WNY Kaleida HealthChief, Division of Endocrinology Distinguished Professor of Medicine State University of New York at Buffalo

P. Barton Duell, MDDirector, Lipid-Atherosclerosis LaboratoryDirector, Lipid Disorders ClinicDivision of Endocrinology, Diabetes & Clinical NutritionOregon Health and Science University

Sergio Fazio, MDCornelius Vanderbilt Professor of MedicineProfessor of Pathology, Immunology & MicrobiologyChief, Cardiovascular Disease PreventionVanderbilt University Medical Center

Keith C. Ferdinand, MDProfessor of Clinical Medicine Tulane University School of MedicineChair, National Forum for Heart Disease & Stroke Prevention

Vivian Fonseca, MD Professor of Medicine and PharmacologyTullis Tulane Alumni Chair in DiabetesChief, Section of EndocrinologyTulane University Health Sciences Center

JoAnne Foody, MD Medical Director Cardiovascular Wellness Program Brigham and Women’s Hospital Associate Professor Harvard Medical School

Ken Fujioka, MDDirector, Nutrition & Metabolic ResearchDirector, Center for Weight ManagementDepartment of EndocrinologyScripps Clinic

W. Timothy Garvey, MDButterworth Professor and ChairDepartment of Nutrition ScienceUniversity of Alabama at BirminghamGRECC Investigator & Staff PhysicianBirmingham VA Medical CenterDir., UAB Diabetes Research Center

Samuel Klein, MDWilliam H. Danforth Professor of Medicineand Nutritional ScienceChief, Division of Geriatrics and Nutritional SciencesDirector, Center for Human NutritionWashington University School of Medicine

J. Michael Gaziano, MDScientific Dir., Massachusetts Veterans Epidemiology Research & Information Ctr.VA Boston Healthcare SystemChief, Division of AgingBrigham and Women’s HospitalProf. of Medicine, Harvard Medical School

Thomas Giles, MDClinical Professor of MedicineHeart and Vascular InstituteTulane University School of Medicine

Robert Harrington, MDArthur L. Bloomfield Professor of MedicineChair, Department of MedicineStanford University

Irl Hirsch, MDProfessor of MedicineDivision of Metabolism, Endocrinology & NutritionUniv. of Washington School of Medicine

Terry Jacobson, MDProfessor of Medicine, Emory UniversityDirector, Office of Health Promotion & Disease PreventionCo-Dir., Lipid & CV Risk Reduction Program Grady Health Systems

Peter Jones, MDAssociate Professor of MedicineCtr. for Cardiovascular Disease PreventionMethodist DeBakey Heart and Vascular Ctr.Baylor College of Medicine

Lee M. Kaplan, MDAssociate Professor of MedicineHarvard Medical SchoolDirector, Obesity, Metabolism & Nutrition InstituteMassachusetts General Hospital

C. Ronald Kahn, MDMary K. Iacocca ProfessorHarvard Medical School Chief Academic OfficerJoslin Diabetes Center

14

Dis

tingu

ishe

d Fa

culty

Distinguished Faculty

Patrick Moriarty, MDDirector Atherosclerosis/LDL-Apheresis CenterProfessor of MedicineUniversity of Kansas Medical Center

David Morrow, MDDir., Levine Cardiac Intensive Care UnitCardiovascular Division Brigham and Women’s HospitalSenior Investigator, TIMI Study GroupAssociate ProfessorHarvard Medical School

Luigi Meneghini, MDProfessor of Clinical MedicineDivision of Endocrinology, Diabetes & MetabolismDirector, Kosow Diabetes Treatment CenterDiabetes Research InstituteUniv. of Miami Miller School of Medicine

Barbara Millen, DrPH, RDPresident Millennium Prevention, Inc. Director Boston Nutrition Foundation, Inc.

Paul Ridker, MDDirector, Center for CardiovascularDisease Prevention Brigham and Women’s HospitalEugene Braunwald Professor of MedicineHarvard Medical School

Gary Puckrein, PhD President and Chief Executive OfficerNational Minority Quality Forum

Daniel Rader, MD Cooper-McClure Prof. of Medicine & Pharmacology Chief, Division of Translational Medicine & Human Genetics Perelman School of Medicine, Univ. of PennsylvaniaAssociate Director, Penn’s Institute for Translational Medicine & Therapeutics

E. Magnus Ohman, MD Professor of MedicineThe Kent and Siri Rawson Director Duke Prgm. for Advanced Coronary DiseaseAssociate Director, Duke Heart CenterDuke University Medical Center

Anne Peters, MDProfessor, Keck School of MedicineDirector, Clinical Diabetes ProgramsUniversity of Southern California

Jorge Plutzky, MDDirector Vascular Disease Prevention Prgm/Lipid ClinicCo-Director, Preventive CardiologyCardiovascular DivisionBrigham and Women’s Hospital

Richard Pratley, MDDir., Florida Hospital Diabetes InstituteSr., Scientist, Translational Research Institutefor Metabolism and DiabetesProfessor, Sanford Burnham Medical Research Institute

Sunder Mudaliar, MDStaff PhysicianVA San Diego Healthcare SystemClinical Professor of MedicineUniversity of California, San Diego

David Nathan, MDDirector Diabetes Center and Clinical Research Ctr.Massachusetts General HospitalProfessor of Medicine Harvard Medical School

Robert Kushner, MDProfessor of MedicineDivision of General Internal MedicineNorthwestern University Feinberg School of MedicineClinical Director, Northwestern Comprehensive Center on Obesity

I-Min Lee, MD, ScDProf. of Medicine, Harvard Medical SchoolProf. of EpidemiologyHarvard School of Public HealthAssociate EpidemiologistBrigham and Women’s Hospital

David Ludwig, MDDirector, New Balance Foundation Obesity Prevention CenterDirector, Optimal Weight for Life ClinicBoston Children’s HospitalProf., Pediatrics, Harvard Medical SchoolProf., Nutrition, Harvard School of Public Health

Peter Libby, MDChief, Cardiovascular Medicine Brigham and Women’s Hospital Mallinckrodt Professor of Medicine Harvard Medical School

Peter McCullough, MDConsultant CardiologistChief, Division of Nutrition & Preventive MedicineWilliam Beaumont HospitalClinical Professor of Health ScienceOakland UniversityWilliam Beaumont School of Medicine

Darren McGuire, MDProfessor of MedicineUniversity of Texas Southwestern Medical Center

Mikhail Kosiborod, MDClinical Associate ProfessorUniversity of Missouri – Kansas CityCardiologistSaint Luke’s Hospital of Kansas City

15

Distinguished Faculty

Distinguished Faculty

Francesco Rubino, MDCatholic University of RomeItaly

Marc Sabatine, MD Chairman, TIMI Study GroupAssociate Physician in CV MedicineBrigham and Women’s HospitalAssociate Professor of MedicineHarvard Medical School

Benjamin Scirica, MDAttending CardiologistBrigham and Women’s HospitalAssistant Professor of MedicineHarvard Medical SchoolInvestigator, TIMI Study Group

Daniel Simon, MD Dir., Harrington Heart & Vascular InstituteChief, Div. of Cardiovascular MedicineUniversity Hospitals Case Medical CenterHerman K. Hellerstein Professor of Cardiovascular ResearchCase Western Reserve University

Arya Sharma, MDProfessor of MedicineChair, Obesity Research & ManagementUniversity of AlbertaClinical Co-Chair, Alberta Health Services Obesity Program

Steven Smith, MDScientific DirectorTranslational Research Institute ProfessorSanford Burnham Medical Research Institute

Laurence Sperling, MDProfessor of Medicine in CardiologyDirector The Center for Heart Disease PreventionEmory University School of Medicine

Evan Stein, MD, PhDVoluntary Professor Laboratory MedicineUniversity of Cincinnati Medical Center

Jean-Claude Tardif, MDDirector, Montreal Heart Institute Research CentreProfessor of Medicine University of Montreal

Raymond Townsend, MDProfessor of MedicineDirector, Hypertension ProgramUniversity of Pennsylvania

Peter Toth, MDSterling Rock Falls ClinicDirector of Preventive CardiologyClinical Associate Professor Dept. of Family and Community MedicineUniv. of Illinois and Southern Illinois Univ.Chief of Medicine, CGH Medical Center

Bernard Zinman, MDDirector Leadership Sinai Center for Diabetes Mount Sinai Hospital Professor of Medicine University of Toronto

Carol Wysham, MD Clinical Associate Professor of MedicineUniversity of Washington-School of MedicineSection Head, Rockwood Center for Diabetesand Endocrinology

William White, MD Professor Univ. of Connecticut School of MedicineChief, Division of Hypertension & Clinical PharmacologyCalhoun Cardiology CenterUniversity of Connecticut Health Center

Michael Weber, MDProfessor of MedicineState University of New YorkDownstate College of Medicine

Tracy Wang, MDAssociate Professor of Medicine in Cardiology Duke University

Sotirios Tsimikas, MD Professor of MedicineDirector of Vascular MedicineDivision of Cardiovascular Diseases,Department of MedicineUniversity of California, San Diego

Collaborate with our expert faculty to decipher the most recent clinical data & the immediate

implications for your patients & practice.

16

Agen

daAgenda

Wednesday, October 2, 2013

12:00 – 1:30pm Lunch Symposium (non-CME) Consider the Role of the Kidney in Type 2 Diabetes Mellitus David S. H. Bell, MB Sponsored by Janssen Pharmaceuticals, Inc. 1:30 – 2:45pm Afternoon Symposium (non-CME) A Novel Treatment Option for Chronic Weight Management Robert Chilton, DO Sponsored by Eisai, Inc. 2:45 – 4:00pm Afternoon Symposium (non-CME) AZOR® and TRIBENZOR®: Fixed-Dose Combination Therapy Robert Busch, MD Sponsored by Daiichi Sankyo, Inc. 2:45 – 4:00pm Afternoon Symposium (non-CME) The Role of the Kidney in T2DM Pathophysiology Paresh Dandona, MD Sponsored by Bristol-Myers Squibb and AstraZeneca LP 4:00 – 5:15pm Afternoon Symposium Cardiometabolic Risk in Racial/Ethnic Minorities: Unique Aspects and Practical Solutions Keith C. Ferdinand, MD; JoAnne Foody, MD; Gary Puckrein, PhD; Laurence Sperling, MD; Tracy Wang, MD Sponsored by the American College of Cardiology in collaboration with the National Minority Quality Forum and the Association of Black Cardiologists 5:15 – 6:45pm Early Evening Symposium (non-CME) Advancements in Cardiometabolic Risk Assessment: Expert Analysis of Recent Evidence and Outcomes Eliot Brinton, MD; Peter McCullough, MD; Peter Toth, MD Sponsored by Atherotech Diagnostics Lab 7:00 – 8:30pm Dinner Symposium (non-CME) Chronic Management of Obesity: The Role of a Unique, Once-Daily Treatment W. Timothy Garvey, MD Sponsored by VIVUS, Inc. 7:00 – 8:30pm Dinner Symposium (non-CME) KYNAMRO (mipomersen sodium) injection: An Overview for Clinicians Sotirios Tsimikas, MD Sponsored by Genzyme, A SANOFI COMPANY

Agenda and faculty are subject to change.

Agenda

17

Customize your CMHC learning experience with our unique mix of plenary presentations, interactive panel discussions and challenging case study sessions.

Thursday, October 3, 2013 6:15 – 7:45am Breakfast Symposium State-of-the-Art Antiplatelet Therapy for Patients with ACS: Expert Analysis & Evidence-Based Guidelines for Optimizing Patient Outcomes Deepak L. Bhatt, MD, MPH; Robert Harrington, MD; E. Magnus Ohman, MD; Marc Sabatine, MD Supported by an educational grant from AstraZeneca 6:15 – 7:45am Breakfast Symposium New Strategies for Obesity Management & Cardiometabolic Risk Reduction: Expert Perspectives on Novel Therapies Targeting the CNS Louis Aronne, MD; Harold Bays, MD; Lee M. Kaplan, MD; Steven Smith, MD Supported by an educational grant from Eisai, Inc. 8:00 – 8:10am Opening Remarks Christie Ballantyne, MD 8:10 – 8:50am Keynote Session Inflammation & Cardiometabolic Risk Peter Libby, MD

8:50 – 10:00am Late-Breaking Clinical Trials & FDA Update Gain expert insight & perspective on how the most recent clinical trial data & FDA decisions will impact your daily practice moderator: Christie Ballantyne, MD discussants: Deepak L. Bhatt, MD, MPH; Robert Eckel, MD; Keith C. Ferdinand, MD; Jay Skyler, MD 10:00 – 11:00am Morning Break/Exhibit Hall Sponsored by Takeda Pharmaceuticals U.S.A., Inc. 11:00am – 12:00pm Hot Topics in ACS: Debate moderator: Deepak L. Bhatt, MD, MPH discussants: Robert Harrington, MD; Daniel Simon, MD

18

Agen

daAgenda

Agenda and faculty are subject to change.

Thursday, October 3, 2013 (cont’d) 12:15 –1:45pm Lunch Symposium Triglyceride & Mixed Dyslipidemia Management: Expert Analysis of Cutting-Edge Data & Evidence-Based Recommendations for Reducing Residual CV Risk Christie Ballantyne, MD; Harold Bays, MD; Deepak L. Bhatt, MD, MPH; Sergio Fazio, MD; Terry Jacobson, MD Supported by an educational grant from Amarin Pharma, Inc. 12:15 – 1:45pm Lunch Symposium Alternate Pathways for the Management of Type 2 Diabetes: Expert Analysis on Targeting Dopamine & the CNS for Glycemic Control & CV Risk Reduction David S. H. Bell, MB; Samuel Dagogo-Jack, MD; J. Michael Gaziano, MD; Jay Skyler, MD Supported by an educational grant from Santarus, Inc. 12:15 – 1:45pm Lunch Symposium Personalized SIHD Management: Evidence-Based Decision Making for Patients at Increased Cardiometabolic Risk JoAnne Foody, MD; Robert Harrington, MD; Mikhail Kosiborod, MD; David Morrow, MD Supported by an independent educational grant from Gilead Sciences, Inc. 2:00 – 2:45pm Keynote Session Translating Insights from Human Genetics into Novel Therapies for Dyslipidemia Daniel Rader, MD

2:45 – 3:30pm Biomarkers vs. Imaging for CV Risk Assessment and Treatment: Debate moderator: Christie Ballantyne, MD discussants: Matthew Budoff, MD; Paul Ridker, MD 3:30 – 4:15pm Afternoon Break/Exhibit Hall 4:15 – 5:15pm Clinical Controversies in Lipid Management: Case-Based Presentations & Discussion moderator: Christie Ballantyne, MD presenters: Harold Bays, MD; Robert Eckel, MD; JoAnne Foody, MD

5:15pm Closing Remarks Christie Ballantyne, MD 5:30 – 6:30pm Welcome Reception

19

Agenda

Thursday, October 3, 2013 (cont’d) 7:00 – 9:00pm Dinner Symposium The Next-Generation of Weight-Loss Medications: Expert Recommendations for Managing Obesity, Diabetes & Cardiometabolic Risk Robert Eckel, MD; W. Timothy Garvey, MD; Samuel Klein, MD; Robert Kushner, MD; Arya Sharma, MD Supported by an educational grant from VIVUS, Inc. 7:00 – 9:00pm Dinner Symposium Personalized T2DM Management: The Role of Incretin Therapies Along the Continuum of Care Robert Chilton, DO; Richard Pratley, MD; Benjamin Scirica, MD; Carol Wysham, MD This activity is supported by an independent medical education grant from Bristol-Myers Squibb and AstraZeneca LP

Friday, October 4, 2013 6:15 – 7:45am Breakfast Symposium Next-Generation Vasodilating Beta Blockers Along the HTN Continuum of Care: Expert Recommendations for Targeting Endothelial Dysfunction, BP and Cardiometabolic Risk George Bakris, MD; Keith C. Ferdinand, MD; Thomas Giles, MD; Michael Weber, MD Supported by an educational grant from Forest Laboratories, Inc. 6:15 – 7:45am Breakfast Symposium State-of-the-Art Management of Severe and Familial Hypercholesterolemia: Examining the Role of Antisense Therapy in Clinical Practice P. Barton Duell, MD; Peter Jones, MD; Patrick Moriarty, MD; Evan Stein, MD Supported by an educational grant from Genzyme, A SANOFI COMPANY 8:00 – 8:10am Opening Remarks Jay Skyler, MD 8:10 – 8:40am Personalized Diabetes Management: Selecting the Right Therapy John Buse, MD 8:40 – 9:10am Insulin Therapy: The State-of-the-Science Irl Hirsch, MD 9:10 – 9:50am T1DM 2013: Translating the Latest Advances into Clinical Practice Robert Eckel, MD; Jay Skyler, MD 9:50 – 10:50am Morning Break/Exhibit Hall 10:50 – 11:30am Pediatric Obesity & T2DM moderator: Jay Skyler, MD presenters: Sonia Caprio, MD; David Ludwig, MD

20

Agen

da

Friday, October 4, 2013 (cont’d) 11:30am – 12:15pm Diabetes Panel Discussion & Audience Q&A moderator: Jay Skyler, MD discussants: John Buse, MD; Sonia Caprio, MD; Robert Eckel, MD; Irl Hirsch, MD; David Ludwig, MD

12:30 – 2:00pm Lunch Symposium Advances in Basal Insulin Therapy: Expert Analysis of Novel Formulations, Combination Therapies & Delivery Technologies John Buse, MD; Irl Hirsch, MD; Luigi Meneghini, MD; Bernard Zinman, MD Supported by an educational grant from Novo Nordisk, Inc. 12:30 – 2:00pm Lunch Symposium Getting to the Heart of Diabetic Dyslipidemia in High-Risk Patients: Clinical Dilemmas & Novel Approaches to Cardiovascular Risk Reduction Darren McGuire, MD; Sunder Mudaliar, MD; Jorge Plutzky, MD; Jean-Claude Tardif, MD Supported by an educational grant from Genentech, A Member of the Roche Group

2:15 – 2:45pm Elevated Serum Creatinine: Different Meaning in Different Settings? George Bakris, MD 2:45 – 3:15pm CKD Endpoints in Clinical Trials: Guidance for Clinical Practice Glenn Chertow, MD 3:15 – 4:00pm Afternoon Break/Exhibit Hall 4:00 – 4:30pm Alternative Therapies for HTN: Examining the Evidence Robert Brook, MD 4:30 – 5:30pm Clinical Controversies in HTN Management: Expert Perspectives & Discussion moderator: George Bakris, MD discussants: Rajiv Agarwal, MD; Raymond Townsend, MD; William White, MD 5:30pm Closing Remarks George Bakris, MD 6:30 – 8:30pm Dinner Symposium Obesity Management 2013: Expert Perspectives on the Clinical Impact of Novel & Emerging Therapies Caroline Apovian, MD; Robert Eckel, MD; Ken Fujioka, MD; Robert Kushner, MD Supported by an educational grant from Novo Nordisk, Inc. 6:30 – 8:30pm Dinner Symposium CV Outcomes for Oral & Incretin-Based Therapies: Examining Cutting-Edge Data & Clinical Implications for Patient Care George Bakris, MD; William Cushman, MD; Vivian Fonseca, MD; William White, MD This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region

Agenda

21

Agenda

Agenda and faculty are subject to change.

Saturday, October 5, 2013 6:15 – 7:45am Breakfast Symposium State-of-the-Art Advances in T2DM Management: Expert Analysis of New & Emerging GLP-1 Receptor Agonists Thomas Blevins, MD; Anne Peters, MD; Carol Wysham, MD Supported by an educational grant from Lilly USA, LLC

8:00 – 8:10am Opening Remarks Robert Eckel, MD

8:10 – 9:00am Keynote Session Brown Fat: Is It Important to Body Weight and Metabolic Risk in Humans? C. Ronald Kahn, MD 9:00 – 9:30am Metabolic Surgery 2013: Patient Selection and Outcomes Francesco Rubino, MD 9:30 – 10:00am Look AHEAD: Interpreting the Results for Clinical Practice David Nathan, MD 10:00 – 10:15am Morning Break 10:15 – 11:00am Diet & Exercise: What’s the Optimal Prescription? moderator: Robert Eckel, MD discussants: I-Min Lee, MD, ScD; Barbara Millen, DrPH, RD 11:00 – 11:30am Clinical Management of Obesity-Related NAFLD Samuel Klein, MD

11:30 – 11:50am Obesity Medicine: Practical Pointers for Your Office or Clinic Robert Kushner, MD 11:50am – 12:30pm Clinical Challenges & Practical Strategies for Obesity Management moderator: Robert Eckel, MD discussants: C. Ronald Kahn, MD; Samuel Klein, MD; Robert Kushner, MD; I-Min Lee, MD, ScD; Barbara Millen, DrPH, RD; David Nathan, MD; Francesco Rubino, MD 12:30pm Closing Remarks Robert Eckel, MD

VASCEPA is covered on the majority of plans with minimal restrictions.

Limitations of Use for Vascepa• The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.• The effect of VASCEPA on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not

been determined.

Vascepa significantly reduced TG levels without increasing LDL-C1 Vascepa significantly improved multiple lipid parameters1,2

Vascepa dose is 4 g/day, 2 capsules twice daily with food1Vascepa demonstrated a tolerability and side-effect profile similar to placebo1,2

• The most common adverse event occurring at an incidence >2% and greater than placebo was arthralgia (2.3% for VASCEPA vs 1.0% for placebo)*

Median baseline (mg/dL)

-35

-30

-25

-20

-15

-10

-5

0

TGs

680

LDL-C

91

Placebo-Adjusted Median Percent Change From Baseline1,2

-2%(NS)

-33%(p<0.001) VASCEPA 4 g/day

n=76

n The effects of VASCEPA 4 grams per day were assessed in a 12-week, randomized, placebo-controlled, double-blind, parallel-group study evaluating patients with fasting TG levels ≥500 mg/dL and ≤2000 mg/dL (with or without statin therapy).1

n The primary study end point was the placebo-adjusted median percent change in TG levels from baseline.2

n TGs: VASCEPA, 27% median decrease from baseline; placebo (n=75), 10% increase.

n LDL-C: VASCEPA, 5% median decrease from baseline; placebo (n=75), 3% decrease.NS=not significant.

-30

-20

-15

-10

-5

0

-25

-4% (NS)

-16% (p<0.001)

-29% (p<0.05)

-18% (p<0.001)

-9% (p<0.05)

Median baseline (mg/dL)

Placebo-Adjusted Median Percent Change From Baseline1,2

HDL-C

27

TC

254

VLDL-C

123

non–HDL-C

225

Apo B

121

n VASCEPA 4 g/day, n=76; placebo, n=75.

n Apo B: VASCEPA, 4% median decrease from baseline; placebo, 4% increase.

n Non–HDL-C: VASCEPA, 8% median decrease from baseline; placebo, 8% increase.

n TC: VASCEPA, 7% median decrease from baseline; placebo, 8% increase.

n VLDL-C: VASCEPA, 20% median decrease from baseline; placebo, 14% increase.

n HDL-C: VASCEPA, 4% median decrease from baseline; placebo, no change.NS=not significant.

Please see Brief Summary on the inside back cover or for full Prescribing Information for VASCEPA, visit www.VASCEPA.com or visit us at booth 301.

References: 1. VASCEPA [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2013. 2. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108(5):682-690.

*Studies included patients with TG levels of 200 to 2000 mg/dL.

For the treatment of severe hypertriglyceridemia (triglyceride levels ≥500 mg/dL)

VASCEPA®

TG Therapy Redefined:VASCEPA significantly reduced TG levels without increasing LDL-C 1

130411 08/13

VASCEPA® (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.

COM

E VIS

IT

AT BOOTH

301

Important safety Information for Vascepa• VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.• Use with caution in patients with known hypersensitivity to fish and/or shellfish. • The most common reported adverse reaction (incidence >2% and greater than placebo) was arthralgia. • Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA.• Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

Apo B=Apolipoprotein B; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; TC=total cholesterol; VLDL-C=very low-density lipoprotein cholesterol.

AMVAUS13X143_CHMC_Pocket_Guide_M07.indd 2-3 9/6/13 2:34 PM

VASCEPA is covered on the majority of plans with minimal restrictions.

Limitations of Use for Vascepa• The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.• The effect of VASCEPA on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not

been determined.

Vascepa significantly reduced TG levels without increasing LDL-C1 Vascepa significantly improved multiple lipid parameters1,2

Vascepa dose is 4 g/day, 2 capsules twice daily with food1Vascepa demonstrated a tolerability and side-effect profile similar to placebo1,2

• The most common adverse event occurring at an incidence >2% and greater than placebo was arthralgia (2.3% for VASCEPA vs 1.0% for placebo)*

Median baseline (mg/dL)

-35

-30

-25

-20

-15

-10

-5

0

TGs

680

LDL-C

91

Placebo-Adjusted Median Percent Change From Baseline1,2

-2%(NS)

-33%(p<0.001) VASCEPA 4 g/day

n=76

n The effects of VASCEPA 4 grams per day were assessed in a 12-week, randomized, placebo-controlled, double-blind, parallel-group study evaluating patients with fasting TG levels ≥500 mg/dL and ≤2000 mg/dL (with or without statin therapy).1

n The primary study end point was the placebo-adjusted median percent change in TG levels from baseline.2

n TGs: VASCEPA, 27% median decrease from baseline; placebo (n=75), 10% increase.

n LDL-C: VASCEPA, 5% median decrease from baseline; placebo (n=75), 3% decrease.NS=not significant.

-30

-20

-15

-10

-5

0

-25

-4% (NS)

-16% (p<0.001)

-29% (p<0.05)

-18% (p<0.001)

-9% (p<0.05)

Median baseline (mg/dL)

Placebo-Adjusted Median Percent Change From Baseline1,2

HDL-C

27

TC

254

VLDL-C

123

non–HDL-C

225

Apo B

121

n VASCEPA 4 g/day, n=76; placebo, n=75.

n Apo B: VASCEPA, 4% median decrease from baseline; placebo, 4% increase.

n Non–HDL-C: VASCEPA, 8% median decrease from baseline; placebo, 8% increase.

n TC: VASCEPA, 7% median decrease from baseline; placebo, 8% increase.

n VLDL-C: VASCEPA, 20% median decrease from baseline; placebo, 14% increase.

n HDL-C: VASCEPA, 4% median decrease from baseline; placebo, no change.NS=not significant.

Please see Brief Summary on the inside back cover or for full Prescribing Information for VASCEPA, visit www.VASCEPA.com or visit us at booth 301.

References: 1. VASCEPA [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2013. 2. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108(5):682-690.

*Studies included patients with TG levels of 200 to 2000 mg/dL.

For the treatment of severe hypertriglyceridemia (triglyceride levels ≥500 mg/dL)

VASCEPA®

TG Therapy Redefined:VASCEPA significantly reduced TG levels without increasing LDL-C 1

130411 08/13

VASCEPA® (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.

COM

E VIS

IT

AT BOOTH

301

Important safety Information for Vascepa• VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.• Use with caution in patients with known hypersensitivity to fish and/or shellfish. • The most common reported adverse reaction (incidence >2% and greater than placebo) was arthralgia. • Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA.• Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

Apo B=Apolipoprotein B; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; TC=total cholesterol; VLDL-C=very low-density lipoprotein cholesterol.

AMVAUS13X143_CHMC_Pocket_Guide_M07.indd 2-3 9/6/13 2:34 PM

1 INDICATIONS AND USAGEVASCEPA® (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet and exercise regimen before receiving VASCEPA and should continue this diet and exercise regimen with VASCEPA.Attempts should be made to control any medical problems such as diabetes mellitus, hypothyroidism, and alcohol intake that may contribute to lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed, if possible, prior to consideration of TG-lowering drug therapy.Limitations of Use:The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.The effect of VASCEPA on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.2 DOSAGE AND ADMINISTRATIONAssess lipid levels before initiating therapy. Identify other causes (e.g., diabetes mellitus, hypothyroidism, or medications) of high triglyceride levels and manage as appropriate. [see Indications and Usage (1)].Patients should engage in appropriate nutritional intake and physical activity before receiving VASCEPA, which should continue during treatment with VASCEPA. The daily dose of VASCEPA is 4 grams per day taken as 2 capsules twice daily with food.Patients should be advised to swallow VASCEPA capsules whole. Do not break open, crush, dissolve, or chew VASCEPA.4 CONTRAINDICATIONSVASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.5 WARNINGS AND PRECAUTIONS5.1 Monitoring: Laboratory TestsIn patients with hepatic impairment, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be monitored periodically during therapy with VASCEPA.5.2 Fish AllergyVASCEPA contains ethyl esters of the omega-3 fatty acid, eicosapentaenoic acid (EPA), obtained from the oil of fish. It is not known whether patients with allergies to fish and/or shellfish are at increased risk of an allergic reaction to VASCEPA. VASCEPA should be used with caution in patients with known hypersensitivity to fish and/or shellfish.6 ADVERSE REACTIONS6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions reported in at least 2% and at a greater rate than placebo for patients treated with VASCEPA based on pooled data across two clinical studies are listed in Table 1.Table 1. Adverse Reactions Occurring at Incidence >2% and Greater than Placebo in Double-Blind, Placebo-Controlled Trials*

Adverse Reaction

Placebo(N=309)

VASCEPA(N=622)

n % n %Arthralgia 3 1.0 14 2.3

*Studies included patients with triglycerides values of 200 to 2000 mg/dL.An additional adverse reaction from clinical studies was oropharyngeal pain.

7 DRUG INTERACTIONS7.1 Anticoagulants Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in those studies has not exceeded normal limits and did not produce clinically significant bleeding episodes. Patients receiving treatment with VASCEPA and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.8 USE IN SPECIFIC POPULATIONS8.1 PregnancyPregnancy Category C: There are no adequate and well-controlled studies in pregnant women. It is unknown whether VASCEPA can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. VASCEPA should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus.In pregnant rats given oral gavage doses of 0.3, 1 and 2 g/kg/day icosapent ethyl from gestation through organogenesis all drug treated groups had visceral or skeletal abnormalities including: 13th reduced ribs, additional liver lobes, testes medially displaced and/or not descended at human systemic exposures following a maximum oral dose of 4 g/day based on body surface comparisons. Variations including incomplete or abnormal ossification of various skeletal bones were observed in the 2 g/kg/day group at 5 times human systemic exposure following an oral dose of 4 g/day based on body surface area comparison.

In a multigenerational developmental study in pregnant rats given oral gavage doses of 0.3, 1, 3 g/kg/day ethyl-EPA from gestation day 7-17, an increased incidence of absent optic nerves and unilateral testes atrophy were observed at ≥0.3 g/kg/day at human systemic exposure following an oral dose of 4 g/day based on body surface area comparisons across species. Additional variations consisting of early incisor eruption and increased percent cervical ribs were observed at the same exposures. Pups from high dose treated dams exhibited decreased copulation rates, delayed estrus, decreased implantations and decreased surviving fetuses (F2) suggesting multigenerational effects of ethyl-EPA at 7 times human systemic exposure following 4 g/day dose based on body surface area comparisons across species.In pregnant rabbits given oral gavage doses of 0.1, 0.3, and 1 g/kg/day from gestation through organogenesis there were increased dead fetuses at 1 g/kg/day secondary to maternal toxicity (significantly decreased food consumption and body weight loss).In pregnant rats given ethyl-EPA from gestation day 17 through lactation day 20 at 0.3, 1, 3 g/kg/day complete litter loss was observed in 2/23 litters at the low dose and 1/23 mid-dose dams by post-natal day 4 at human exposures based on a maximum dose of 4 g/day comparing body surface areas across species. 8.3 Nursing MothersStudies with omega-3-acid ethyl esters have demonstrated excretion in human milk. The effect of this excretion is unknown; caution should be exercised when VASCEPA is administered to a nursing mother. In lactating rats, given oral gavage 14C-ethyl EPA, drug levels were 6 to 14 times higher in milk than in plasma.8.4 Pediatric UseSafety and effectiveness in pediatric patients have not been established.8.5 Geriatric UseOf the total number of subjects in clinical studies of VASCEPA, 33% were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.9 DRUG ABUSE AND DEPENDENCEVASCEPA does not have any known drug abuse or withdrawal effects.13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of FertilityIn a 2-year rat carcinogenicity study with oral gavage doses of 0.09, 0.27, and 0.91 g/kg/day icosapent ethyl, respectively, males did not exhibit drug-related neoplasms. Hemangiomas and hemangiosarcomas of the mesenteric lymph node, the site of drug absorption, were observed in females at clinically relevant exposures based on body surface area comparisons across species relative to the maximum clinical dose of 4 g/day. Overall incidence of hemangiomas and hemangiosarcomas in all vascular tissues did not increase with treatment.In a 6-month carcinogenicity study in Tg.rasH2 transgenic mice with oral gavage doses of 0.5, 1, 2, and 4.6 g/kg/day icosapent ethyl, drug-related incidences of benign squamous cell papilloma in the skin and subcutis of the tail was observed in high dose male mice. The papillomas were considered to develop secondary to chronic irritation of the proximal tail associated with fecal excretion of oil and therefore not clinically relevant. Drug-related neoplasms were not observed in female mice.Icosapent ethyl was not mutagenic with or without metabolic activation in the bacterial mutagenesis (Ames) assay or in the in vivo mouse micronucleus assay. A chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells was positive for clastogenicity with and without metabolic activation.In an oral gavage rat fertility study, ethyl-EPA, administered at doses of 0.3, 1, and 3 g/kg/day to male rats for 9 weeks before mating and to female rats for 14 days before mating through day 7 of gestation, increased anogenital distance in female pups and increased cervical ribs were observed at 3 g/kg/day (7 times human systemic exposure with 4 g/day clinical dose based on a body surface area comparison).17 PATIENT COUNSELING INFORMATION17.1 Information for PatientsSee VASCEPA Full Package Insert for Patient Counseling Information

VASCEPA® (icosapent ethyl) Capsules, for oral useBrief summary of Prescribing InformationPlease see Full Prescribing Information for additional information about VASCEPA®.

Distributed by: Amarin Pharma Inc., Bedminster, NJ, USAManufactured by: Banner Pharmacaps, Tilburg, The Netherlands or Catalent Pharma Solutions, LLC, St. Petersburg, FL, USAManufactured for: Amarin Pharmaceuticals Ireland Limited, Dublin, Ireland

Amarin Pharma Inc. Bedminster, NJ 07921www.vascepa.com © 2012 Amarin Pharmaceuticals Ireland LimitedAll rights reserved130372 07/13

AMVAUS13X143_CHMC_Pocket_Guide_M07.indd 4 9/6/13 2:34 PM

Industry Supporters & SponsorsThe 2013 CMHC gratefully acknowledges the educational grant support and

sponsorship provided by the following organizations.

Platinum Supporters

Gold Supporters

Gold Sponsors

Silver Sponsors

Bronze Supporter

Industry Supporters & Sponsors

25

26For information on becoming a 2014 CMHC Association Supporter,

contact CMHC at 877.571.4700

Association SupportersThe 2013 CMHC gratefully acknowledges our Association Supporters.

American Heart AssociationCouncils on High Blood Pressure Research;

Stroke; Epidemiology & Prevention;CV Disease in the Young; Basic CV Sciences; Nutrition, Physical Activity & Metabolism;

CV Nursing; Clinical Cardiology;Kidney in CV Disease

INCORPORATEDA.C.N.

AMERICAN

CO

LLEGE OF NUTRITIO

N

Association of Physicians Assistants

in Cardiology

Metropolitan New York Association of Diabetes Educators

New Jersey Coordinating Body of AADE

San Francisco Bay Area Association of Diabetes Educators

EUROPEAN COLLEGE OF PREVENTIVE AND LIFESTYLE MEDICINE

ECLM

Ass

ocia

tion

Supp

orte

rs

iPad mini GIVEAWAY

Visit each booth in the CMHC Exhibit Hall for a chance to win an iPad Mini!

Each booth you have your name badge scanned at will count toward one entry

into the raffle. So visit as many booths as you can. Good Luck!!

Raffle entry deadline is Friday, October 4 at 5:00pm.Winner to be announced Saturday, October 5 during the General Session.

For information on becoming a 2014 CMHC Association Supporter, contact CMHC at 877.571.4700

Daiichi Sankyo is a global pharmaceutical company with its corporate origin in Japan. We provide innovative products and services in more than 50 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and medical advancements.

Building on our experience in hypertension, antiplatelet, and anticoagulation therapies, we are excited to be expanding into other important areas such as oncology, where significant unmet medical needs remain. Today, with our growing presence in developing and emerging markets, we are pleased to serve the needs of patients throughout the world.

Discover more at www.DSI.com

©2013 Daiichi Sankyo, Inc. DSNA13101249 Printed in USA 08/13

VISIT BOOTH #607 AND LEARN MORE ABOUT HOW OUR PRODUCTS CAN HELP YOUR PATIENTS

Daiichi Sankyo is a global pharmaceutical company with its corporate origin in Japan. We provide innovative products and services in more than 50 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and medical advancements.

Building on our experience in hypertension, antiplatelet, and anticoagulation therapies, we are excited to be expanding into other important areas such as oncology, where significant unmet medical needs remain. Today, with our growing presence in developing and emerging markets, we are pleased to serve the needs of patients throughout the world.

Discover more at www.DSI.com

©2013 Daiichi Sankyo, Inc. DSNA13101249 Printed in USA 08/13

VISIT BOOTH #607 AND LEARN MORE ABOUT HOW OUR PRODUCTS CAN HELP YOUR PATIENTS

30

Exhi

bito

rs G

uide

Exhibit Hall Floor PlanHynes Convention Center

9:00am – 12:00pm 2:00pm – 5:00pm

9:30am – 12:00pm 2:30pm – 6:45pm

Hours of Operation

Thursday, October 3 Friday, October 4

Join us . . . in the Exhibit Hall for our Welcome Reception Thursday, October 3 • 5:30pm - 6:30pm

31

Exhibitors Guide

Exhibitors Booth NumberAegerion Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .518Amarin Pharma Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .301Amgen Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .409AstraZeneca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .619AstraZeneca/Bristol-Myers Squibb . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .601AstraZeneca/Bristol-Myers Squibb . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .212Atherotech Diagnostics Lab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .206Bariatrix Nutrition Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .420BD - Diabetes Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .202BMIQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .120Boehringer Ingelheim Pharmaceuticals, Inc/Lilly, USA. . . . . . . . . . . . . . . . . . . . . . . . . . . .407Boston Heart Diagnostics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .214Daiichi Sankyo, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .607diaDexus, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .613Eisai, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .513ETHICON . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .313Everidis Health Sciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .215Forest Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .307Genova Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .200Genzyme, A SANOFI COMPANY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .312Gilead Sciences, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .506Health Diagnostic Laboratory, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .315Ideal Protein of America . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .615Infinite Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .319Janssen Pharmaceuticals, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .406Kaneka Pharma America, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .508Kowa Pharmaceuticals America, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .418LD Technology, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .321LipoScience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .412LipoScience Global Research Services. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .419LipoScience Presentation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .413Merck & Co., Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .201Novo Nordisk, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .218Otsuka America Pharmaceutical, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .421Pure Encapsulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213Santarus, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .309SleepImage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .512Vital Nutrients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .514VIVUS, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .401

Join us . . . in the Exhibit Hall for our Welcome Reception Thursday, October 3 • 5:30pm - 6:30pm

Aegerion Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 518101 Main Street, Suite 1850 Cambridge, MA 02142 email: infogroup@aegerion.comweb: www.aegerion.comAegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating often fatal, rare diseases. Our initial focus is to bring novel therapies to patients with severe lipid disorders.

Amarin Pharma Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3011430 Route 206, Suite 200 Bedminster, NJ 07921web: www.amarincorp.comAmarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Amgen Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 409One Amgen Center Drive Thousand Oaks, CA 91320-1799web: www.amgen.comAmgen, a biotechnology pioneer, discovers, develops, and delivers innovative human therapeutics. Our medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, we continue to advance science to serve patients.

AstraZeneca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6195 Steere Road Cumberland, RI 02864 tel: 401-360-7412web: www.astrazeneca.comAstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca/Bristol-Myers Squibb . . . . . . . . . . . . . . . . . . . 212, 601777 Scudders Mill Rd. Plainsboro, NJ 08536 tel: 609-897-2000web: www.astrazeneca.com web: www.bms.comDedicated to addressing the global burden of diabetes by advancing individualized patient care, AstraZeneca and Bristol-Myers Squibb are working in collaboration to research, develop and commercialize a versatile portfolio of innovative treatment options for diabetes and related metabolic disorders.32

Exhi

bito

rs G

uide

Exhibitors Guide

33

Exhibitors Guide

Atherotech Diagnostics Lab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206201 London Parkway Birmingham, AL 35211 email: custservreqs@atherotech.comweb: www.atherotech.comAtherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary and comprehensive VAP® Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The VAP technology reveals residual risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP Lipid Panel utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST

Bariatrix Nutrition Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42010 Ossipee Rd Newton Upper Falls, MA 02464 tel: 800-468-3438 email: info@bariatrixgroup.comweb:www.bariatrix.comFor more than three decades, Bariatrix Nutrition Group has been a trusted leader in the field of professionally directed weight management. We have invested in developing a full suite of products and services to address the most important challenges facing weight loss professionals today. We believe that with our integrated approach, that includes technology-based programs, great-tasting food products and targeted nutraceuticals, patients will lose weight and succeed in adopting new behaviors that lead to sustainable lifestyle change.

BD - Diabetes Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202One Becton St Franklin Lakes, NJ 07417web: www.bd.comIn recent years there has been a major shift toward shorter length needles. Many recommendations that presently exist have little or no underpinning and are based as much on habit and tradition as on evidence. The new evidenced based global injections recommendations provide clear evidence based recommendations for specific populations and stress the need for correct injection technique which is critical for your patient’s optimal glycemic control. Learn about the findings of the largest study ever done in adults with diabetes to measure the skin and subcutaneous thickness and their relation to selecting the proper needle length for your patient which enables the initiation and better outcomes of injectable diabetes therapy.

BMIQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1204250 Veterans Highway Suite 175E Holbrook, NY 11741 tel: 631-676-4802 email: admin@bmiq.comBMIQ provides evidence-based weight control programs developed by Dr. Louis Aronne. The BMIQ Professionals Program is a turnkey solution that provides health care providers with everything needed to deliver an evidence-based program in their office. Provider-branded web site, personalized accounts, session materials for patients and the professional for 20 visits, online tools and resources provide the perfect complement to office visits. Visit our booth for a system and program overview and see how you can get started today!

34

Exhi

bito

rs G

uide

Boehringer Ingelheim Pharmaceuticals, Inc/Lilly, USA . . . . . 407900 Ridgebury Road Ridgefield, CT 06877web: www.us.boehringer-ingelheim.com web: www.lilly.comBoehringer Ingelheim Pharmaceuticals, Inc., and Lilly USA, LLC welcome you to Cardiometabolic Health Congress (CHMC) and look forward to the opportunity to share the latest clinical information on our products. Visit us at www.us.boehringer-ingelheim.com and www.lilly.com.

Boston Heart Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214175 Crossing Blvd, Suite 100 Framingham, MA 01702 email: info@bostonheartdx.comweb: www.bostonheartdiagnostics.comBoston Heart Diagnostics is a heart health management company providing integrated diagnostic and patient management solutions that are advancing cardiovascular disease risk assessment, monitoring and treatment.

Daiichi Sankyo, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6072 Hilton Court Parsippany, NJ 07054web: www.dsi.comDaiichi Sankyo, Inc. (DSI), headquartered in Parsippany, NJ, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd., a global pharmaceutical company. DSI was formed in 2006 from the integration of two leading pharmaceutical companies, Sankyo Pharma, Inc. and Daiichi Pharmaceutical Corporation. Its team of nearly 3,000 U.S. employees is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients. DSI concentrates in the therapy areas of hypertension, thrombosis, dyslipidemia, diabetes and acute coronary syndrome. Clinical development and regulatory activities are headquartered at Daiichi Sankyo Pharma Development in Edison, NJ. Visit www.dsi.com.

diaDexus, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 613349 Oyster Point Blvd South San Francisco, CA 94080web: www.plactest.comdiaDexus, Inc., is a biotechnology company focused on the development and commercialization of novel in vitro diagnostic tests for cardiovascular disease. The PLAC Test for Lp-PLA2 (lipoprotein-associated phospholipase A2) is a blood test that measures the enzyme activity of Lp-PLA2. Lp-PLA2 is a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. Plaque rupture and thrombosis cause the majority of cardiac events. The PLAC Test helps to identify the patients with hidden CVD risk independent from traditional risk factors. Visit www.plactest.com for more information.

Eisai, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 513100 Tice Blvd. Woodcliff Lake, NJ 07677web: www.eisai.com/USEisai Inc. is the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Headquartered in Woodcliff Lake, New Jersey, Eisai’s key areas of commercial focus are neurology and oncology. Eisai’s global product creation organization includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, and manufacturing facilities in Maryland and North Carolina. Established in 1995, the company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. For more information about Eisai, please visit www.eisai.com/US.

Exhibitors Guide

35

Exhibitors Guide

ETHICON . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3134545 Creek Road Cincinnati, OH 45242web: www.ethicon.comEthicon, Inc. and Ethicon Endo-Surgery, Inc., two companies with long histories of medical innovation, do business under the Ethicon brand. Their surgical technologies and products (including sutures, staplers, clip appliers, trocars and meshes) are used around the world to treat colorectal and thoracic conditions, women’s health conditions, hernias, cancer and obesity. Ethicon, Inc. and Ethicon Endo-Surgery, Inc. are part of the Johnson & Johnson Family of Companies.

Everidis Health Sciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2152900 Brannon Avenue St. Louis, MO 63139 tel: 877-776-0101web: www.everidis.comEveridis is an innovative health sciences company focused on developing unique approaches to address nutritional and metabolic deficiencies. We strive to translate peer-reviewed research on health and nutrition into products that are safe, therapeutic and healthful. We are committed to improving patient quality of life.

Forest Pharmaceuticals, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30713600 Shoreline Drive St. Louis, MO 63045 email: info@forestpharm.comweb: www.frx.comForest’s longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective, respiratory, and gastrointestinal medicine. The Company’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas.

Genova Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20063 Zillicoa St. Asheville, NC 28801 tel: 800-522-9303 email: info@gdx.netweb: www.gdx.netHeadquartered in Asheville, N.C., Genova Diagnostics is a global, specialty clinical laboratory, pioneering a systems approach that supports healthcare providers in the personalized treatment and prevention of chronic disease. Chronic diseases are often complex, and Genova Diagnostic’s system-based testing helps physicians develop targeted treatments for their patients. Easy-to-read color graphic reports synthesize test results into actionable information and facilitate better physician-patient communication. The internationally renowned lab is committed to the highest standards and has a robust array of educational resources, as well as a team of medical experts who provide consultation to healthcare practitioners to ensure that physicians order the right tests for their patients.

36

Exhi

bito

rs G

uide

Genzyme, A SANOFI COMPANY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312500 Kendall Street Cambridge, MA 02142web: www.genzyme.comGenzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research, collaboration with the global patient community, and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. Genzyme’s portfolio of transformative therapies which are marketed in countries around the world, represent groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.

Gilead Sciences, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506333 Lakeside Drive Foster City, CA 94404 email: corporate_development@gilead.comweb: www.gilead.comGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases around the world. Gilead’s therapeutic areas of focus include HIV/AIDS, hepatitis, serious respiratory, cardiovascular, and metabolic conditions, cancer and inflammation.

Health Diagnostic Laboratory, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . 315737 N. 5th Street Richmond, VA 23219web: www.hdlabinc.comHealth Diagnostic Laboratory, Inc. (HDL, Inc.) is a leader in health management offering a comprehensive test menu of risk factors and biomarkers for cardiovascular disease, diabetes, and related diseases. HDL, Inc.’s systematic approach identifies factors contributing to disease and can provide a basis for personalized treatment, allowing physicians to more effectively manage patients. Individuals receive a personalized overview of their risk factors along with intensive counseling from expert Clinical Health Consultants at no additional cost, improving compliance and enhancing satisfaction. HDL, Inc. is a CLIA-certified, CAP-accredited laboratory.

Ideal Protein of America . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61560 Jean-Proulx Gatineau, Québec, Canada J8Z1W1 tel: 1-866-314-4447web: www.idealprotein.comIdeal Protein is a medically designed protocol that contains 2 key components- weight loss and a healthier lifestyle education provided by licensed healthcare professionals.

Exhibitors Guide

37

Exhibitors Guide

Infinite Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31968 Route 125 Kingston, NH 03848 tel: 603-347-6006 fax: 603-942-9291 email: info@infinitetherapeutics.comweb: www.infinitymassagechairs.comThe Infinity IT-8800, COMPARABLE TO THE INADATM for 1/2 the price, offers state of the art roller foot reflexology, thigh and hip massage, an amazing spinal decompression stretch, sensors for customized targeted massage, lumbar heat and music, endless luxury, ULTIMATE MASSAGE!

Janssen Pharmaceuticals, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4061000 Route 202 Raritan, NJ 08869web: www.janssenpharmaceuticalsinc.comJanssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer’s disease, epilepsy, migraine prevention and treatment), pain management, cardiovascular, and women’s health. Our ultimate goal is to help people live healthy lives. We have produced and marketed many first-in-class prescription medications and are poised to serve the broad needs of the healthcare market – from patients to practitioners, from clinics to hospitals.

Kaneka Pharma America, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 508546 Fifth Avenue New York, NY 10036web: www.liposorber.comThe LIPOSORBER® System is indicated for use in performing low density lipoprotein cholesterol (LDL-C) apheresis to acutely remove LDL-C from the plasma of the following high risk patient populations for whom diet has been ineffective and maximum drug therapy has either been ineffective or not tolerated: Patients with LDL-C >300 mg/dl , Patients with LDL-C >200 mg/dl and documented coronary heart disease (CHD).

Kowa Pharmaceuticals America, Inc . . . . . . . . . . . . . . . . . . . . . . . . 418530 Industrial Park Blvd Montgomery, AL 36117 tel: 334-288-1288web: www.KowaPharma.comKowa Pharmaceuticals is a specialty pharmaceutical company focused on delivering customer solutions for cardiovascular conditions.Products:Livalo-HMG-CoA reductase inhibitor indicated for patients with primary hyperlipidemia and mixed dyslipidemia.Lipofen – fenofibrate capsule: indicated for patients with hypercholesterolemia, mixed dyslipidemia and patients with severe hypertriglyceridemia.

38

Exhi

bito

rs G

uide

LD Technology, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 321100N Biscayne, Suite 502 Miami, FL 33132web: www.idteck.comLLD Technology, LLC is a US medical device manufacturer, that specializes in the design and development of non-invasive, point-of-care biosensors. Our unique product, combining different technologies, assist physician in identifying cardio metabolic risk factors and Autonomic nervous system dysfunction. Features include early detection of diabetes complications (sudomotor function, autonomic neuropathy, cardiovascular disease) and significantly improve diabetes treatment management (www.ldteck.com).

LipoScience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4122500 Sumner Blvd Raleigh, NC 27616web: www.liposcience.comLipoScience offers the NMR LipoProfile® test. The NMR LipoProfile test measures LDL particle number (LDL-P) and standard lipid parameters to aid in the management of cardiovascular disease using nuclear magnetic resonance (NMR) technology. For more information, please visit www. liposcience.com.

LipoScience Global Research Services . . . . . . . . . . . . . . . . . . . . . . 419 2500 Sumner Blvd Raleigh, NC 27616 tel: 919-256-1230 fax: 919-875-8956 email: djobe@liposcience.comweb: www.liposcience.comLipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR). The NMR LipoProfile test, the company’s first proprietary test, measures LDL particle number (LDL-P) and standard lipids to aid in the management of cardiovascular disease. For more information, please visit www.liposcience.com.

LipoScience Presentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4132500 Sumner Blvd Raleigh, NC 27616web: www.liposcience.comLipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. For more information, please visit www.lipoprofile.com.

Exhibitors Guide

For information regarding 2014 CMHC Exhibit Opportunities,please contact Brittany or Tina

877.571.4700 or info@cardiometabolichealth.org

39

Exhibitors Guide

Merck & Co ., Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201One Merck Drive P.O. Box 100 Whitehouse Station, NJ 08889-0100 tel: 908-423-1000web: www.merck.comToday’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships that donate and deliver our products to the people who need them. For more information, visit www.merck.com.

Novo Nordisk, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218100 College Road West Princeton, NJ 08540 tel: 609-987-5800web: www.novonordisk-us.comNovo Nordisk is a health care company with an 88-year history of innovation and achievement in diabetes care. Novo Nordisk is Changing Diabetes® by helping to improve diabetes care through partnerships, research, products and services that make a significant difference to patients, the medical professional and society at large. Our portfolio of diabetes pharmaceuticals and delivery systems is the most comprehensive available and now includes the first human glucagon-like peptide–1(GLP-1) analog for the treatment of diabetes.

Otsuka America Pharmaceutical, Inc . . . . . . . . . . . . . . . . . . . . . . . 4212440 Research Boulevard Rockville, MD 20850web: www.otsuka-us.comOtsuka America Pharmaceutical, Inc. (OAPI) is an innovative, fast-growing healthcare company that commercializes Otsuka-discovered and in-licensed products in the U.S. With a strong focus on neuroscience, oncology, cardio-renal and medical device, OAPI is dedicated to improving patient health and the quality of human life. OAPI is part of the Otsuka Group companies. For more information, visit www.otsuka-us.com.

Pure Encapsulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213490 Boston Post Road Sudbury, MA 01776web: www.PureEncapsulations.comPure Encapsulations is committed to producing the most complete line of science-based nutritional supplements. Available through health professionals, finished products are pure and hypo-allergenic to optimize the long-term health of the most sensitive patients. Pure Encapsulations is NSF-GMP registered in the U.S., GMP certified in Canada and exceeds the standards of the United States Pharmacopeia (USP) for supplement manufacturing.* Distributed worldwide, Pure Encapsulations products contain the highest quality ingredients in their most bioavailable forms and are formulated to provide strengths and dosing consistent with clinical experience and double-blind, placebo-controlled studies, the gold standard of research design. For additional information, please visit our website.

Santarus, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3093611 Valley Centre Drive, Suite 400 San Diego, CA 92130 tel: 858-314-5700 fax: 858-314-5701 email: contact@santarus.comweb: www.santarus.comSantarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company’s current commercial efforts are focused on five products, of which two are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes.

SleepImage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 512370 Interlocken Blvd. Suite 650 Broomfield, CO 80021 email: sales@sleepimage.comweb: www.sleepimage.comThe SleepImage patient-centered, low cost screening device is the only simple and objective measure of sleep quality. Most home sleep tests only test for sleep apnea, SleepImage tests total sleep health. The SleepImage system offers the first indication of poor sleep, identifying the potential for poor health. At the core of our lightweight, ultra-convenient solution is the proprietary Cardiopulmonary Coupling (CPC) technology. This innovative solution measures sleep quality through breathing and heart rate patterns known to control stable, healthy sleep versus unstable, unhealthy sleep. The SleepImage system offers the only cost effective way to track treatment outcomes over time.

Vital Nutrients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51445 Kenneth Dooley Drive Middletown, CT 06457 email: orders@vitalnutrients.netweb: www.vitalnutrients.netVital Nutrients is an American-owned supplement manufacturer that is widely known as The Leader in Quality Assurance. The Vital Nutrients product line includes 200 science-based and pharmaceutical-grade supplements sold exclusively to healthcare professionals. All products are manufactured in the U.S. at an FDA-Inspected facility. Vital NutrientsQuality Assurance program exceeds industry and regulatory standards. Every batch of raw material and finished product is tested at accredited U.S. independent labs, ensuring purity and potency in every bottle.

VIVUS, Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401351 E. Evelyn Ave Mountain View, CA 94041 email: ir@vivus.comweb: www.vivus.comVIVUS is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity, diabetes, sleep apnea and sexual health. Qsymia is approved as an adjunct to diet and exercise for chronic weight management in adults who are obese or overweight with at least one weight-related comorbidity.

Exhibitors Guide

For information on becoming a 2014 Publication Supporter, contact the CMHC at 877.571.4700.

40

Exhi

bito

rs G

uide

41

Publication SupportersThe 2013 CMHC gratefully acknowledges our Publication Supporters.

For information on becoming a 2014 Publication Supporter, contact the CMHC at 877.571.4700.

Publication Supporters

© 2013 AstraZeneca Pharmaceuticals LP and Bristol-Myers Squibb Company.Onglyza® is a trademark of Bristol-Myers Squibb Company.466US13BR02205-01-01 08/13

43

October 22 − 25, 2014 · Boston, MA

Save the Date!

Exclusive On-Site Registration Offer:Register Today for the 2014 CMHC for Only $195!

The Lowest Rate for the 2014 CMHC!

$500SAVEUP

TO

For the treatment of severe hypertriglyceridemia (triglyceride levels ≥500 mg/dL)

VASCEPA® TG Therapy Redefined:

VASCEPA significantly reduced TG levels without increasing LDL-C1

Reference: 1. VASCEPA [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2013.

Indication and Limitations of Use for VascepaVASCEPA® (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.• The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.• The effect of VASCEPA on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not

been determined.

Important safety Information for Vascepa• VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of

its components.• Use with caution in patients with known hypersensitivity to fish and/or shellfish. • The most common reported adverse reaction (incidence >2% and greater than placebo) was arthralgia. • Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA.• Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

Please see full Prescribing Information at www.VASCEPA.com or visit VASCEPA at booth 301.

Amarin Pharma Inc. Bedminster, NJ 07921© 2012 Amarin Pharmaceuticals Ireland Limited All rights reserved. 130411 08/13

COM

E VIS

IT

AT BOOTH

301

AMVAUS13X143_CHMC_Pocket_Guide_M07.indd 5 9/6/13 2:34 PM